Investors/Media

2017 Press Releases

Keyword Search
Year:
Infinity Pharmaceuticals and Bristol-Myers Squibb Expand Clinical Collaboration Evaluating IPI-549 in Combination with Opdivo (Nivolumab)
Sep 25, 2017
- Collaboration Expands Ongoing Phase 1/1b Study to Include Patients with Triple Negative Breast Cancer Who Have Not Been Previously Exposed to Anti-PD-1 or Anti-PD-L1 Therapy - CAMBRIDGE, Mass., Sept. 25, 2017 /PRNewswire/ -- Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced that it has expanded its existing clinical collaboration with Bristol-Myers Squibb evaluating IPI-549 in combination with Opdivo® to include patients with triple negative breast cancer (TNBC) who have not b... 
Infinity Provides Company Update and Reports Second Quarter 2017 Financial Results
Aug 03, 2017
- Phase 1 Clinical Study Evaluating IPI-549 as a Monotherapy and in Combination with Opdivo® Advancing - - IPI-549 Monotherapy Dose Escalation Completed and Monotherapy Expansion Initiated - - Dose Escalation Evaluating IPI-549 in Combination with Opdivo Ongoing; Combination Expansion Expected to Initiate in the Second Half of 2017 - CAMBRIDGE, Mass., Aug. 3, 2017 /PRNewswire/ -- Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced its second quarter 2017 financial results an... 
Infinity Amends PI3K-Delta,Gamma Agreement with Takeda Oncology
Jul 27, 2017
CAMBRIDGE, Mass., July 27, 2017 /PRNewswire/ -- Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), today announced that it has amended its license agreement with Takeda Oncology for IPI-549, Infinity's potentially first-in-class immuno-oncology product candidate that selectively inhibits phosphoinositide-3-kinase gamma (PI3K-gamma). Under the amended agreement, Infinity will no longer have an obligation to pay Takeda future royalties on worldwide net sales of selective inhibitors of PI3K-gamma, incl... 
Infinity Announces the Date of Its Second Quarter 2017 Financial Results Conference Call and Webcast
Jul 21, 2017
CAMBRIDGE, Mass., July 21, 2017 /PRNewswire/ -- Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) will host a conference call on Thursday, August 3, 2017, at 4:30 p.m. ET to review its second quarter 2017 financial results and provide an update on the company. A live webcast of the conference call can be accessed in the Investors/Media section of Infinity's website at www.infi.com. To participate in the conference call, please dial 1-877-316-5293 (domestic) and 1-631-291-4526 (international) five... 
Infinity to Participate in Three Upcoming Conferences
Jun 14, 2017
CAMBRIDGE, Mass., June 14, 2017 /PRNewswire/ -- Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing IPI-549, a potentially first-in-class immuno-oncology product candidate that selectively inhibits phosphoinositide-3-kinase gamma (PI3K-gamma), today announced that management will be participating in the following three upcoming conferences: JMP Securities Annual Life Sciences Conference: Infinity will participate in the JMP Securities Annual Life... 
Infinity Provides Company Update and Reports First Quarter 2017 Financial Results
May 09, 2017
- Patient Enrollment Ongoing in IPI-549 Dose-Escalation in Phase 1 Clinical Study - - Phase 1 Monotherapy and Combination Expansions Expected to Initiate in the Second Half of 2017 - - Additional Phase 1 Data Anticipated in the Second Half of 2017 - CAMBRIDGE, Mass., May 9, 2017 /PRNewswire/ -- Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced its first quarter 2017 financial results and provided an update on the company, including its progress with IPI-549, a potentially ... 
Infinity Announces the Date of Its First Quarter 2017 Financial Results Conference Call and Webcast
Apr 26, 2017
CAMBRIDGE, Mass., April 26, 2017 /PRNewswire/ -- Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) will host a conference call on Tuesday, May 9, 2017, at 4:30 p.m. ET to review its first quarter 2017 financial results and provide an update on the company. A live webcast of the conference call can be accessed in the Investors/Media section of Infinity's website at www.infi.com. To participate in the conference call, please dial 1-877-316-5293 (domestic) and 1-631-291-4526 (international) five min... 
Updated Phase 1 Data for IPI-549 Presented at AACR Annual Meeting 2017
Apr 01, 2017
- IPI-549 Was Well Tolerated as a Monotherapy and in Combination with Opdivo® in Patients with Advanced Solid Tumors - - Phase 1 Expansion Modules Expected to Initiate in the Second Half of 2017 - WASHINGTON, April 1, 2017 /PRNewswire/ -- Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today reported updated Phase 1 clinical data for IPI-549, an orally administered immuno-oncology development candidate that selectively inhibits phosphoinositide-3-kinase gamma (PI3K-gamma). These Phase 1 cl... 
Infinity Provides Company Update and Reports Fourth Quarter 2016 Financial Results
Mar 14, 2017
- Updated Data from Phase 1 Study of IPI-549 to Be Presented at AACR - - Patient Enrollment in Combination Dose-Escalation Portion of IPI-549 Phase 1 Study Ongoing - - Phase 1 Expansion Cohorts Expected to Initiate in the Second Half of 2017 - CAMBRIDGE, Mass., March 14, 2017 /PRNewswire/ -- Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced its full-year 2016 financial results and provided an update on the company, including its progress with IPI-549, a potentially first-i... 
IPI-549 Featured at 15th International Congress on Targeted Anticancer Therapies
Mar 06, 2017
PARIS, March 6, 2017 /PRNewswire/ -- Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced that Phase 1 clinical data for IPI-549, an orally administered immuno-oncology development candidate that selectively inhibits phosphoinositide-3-kinase gamma (PI3K-gamma), were presented during a plenary session at the 15th International Congress on Targeted Anticancer Therapies (TAT 2017) taking place in Paris, France, March 6 – 8. A Phase 1 clinical study is ongoing to explore the safety and act... 
Infinity Announces Presentation on IPI-549 at AACR Annual Meeting
Mar 02, 2017
- Poster Presentation to Include Updated Data from Ongoing Phase 1 Study of IPI-549 in Patients with Advanced Solid Tumors - CAMBRIDGE, Mass., March 2, 2017 /PRNewswire/ -- Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced that new Phase 1 data for IPI-549, an orally administered immuno-oncology development candidate that selectively inhibits phosphoinositide-3-kinase gamma (PI3K-gamma), will be presented in a clinical trial poster session at the American Association for Cancer ... 
Infinity Announces the Date of Its Full-Year 2016 Financial Results Conference Call and Webcast
Feb 28, 2017
CAMBRIDGE, Mass., Feb. 28, 2017 /PRNewswire/ -- Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) will host a conference call on Tuesday, March 14, 2017, at 4:30 p.m. ET to review its full-year 2016 financial results and provide an update on the company. A live webcast of the conference call can be accessed in the Investors/Media section of Infinity's website at www.infi.com. To participate in the conference call, please dial 1-877-316-5293 (domestic) and 1-631-291-4526 (international) five minut... 
Infinity to Present at 37th Annual Cowen and Company Healthcare Conference
Feb 27, 2017
CAMBRIDGE, Mass., Feb. 27, 2017 /PRNewswire/ -- Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) will be presenting at the Cowen and Company 37th Annual Healthcare Conference on Monday, March 6, 2017, at 4:00 p.m. ET in Boston, MA. A live webcast of Infinity's presentation will be accessible on the Investors/Media section of Infinity's website at www.infi.com, and will be available for 30 days following the event. About Infinity Infinity is an innovative biopharmaceutical company dedicated to a... 
Infinity Announces Promotion of Jeffery Kutok, M.D., Ph.D. to Chief Scientific Officer
Feb 13, 2017
CAMBRIDGE, Mass., Feb. 13, 2017 /PRNewswire/ -- Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced that Jeffery Kutok, M.D., Ph.D. has been promoted to the role of chief scientific officer, effective immediately. In this role, Dr. Kutok will be responsible for overseeing biology and translational science efforts, including preclinical collaborations, to support the ongoing clinical development of IPI-549, Infinity's oral immuno-oncology development candidate that selectively inhibits ... 
Infinity to Present at the 2017 BIO CEO & Investor Conference
Feb 06, 2017
CAMBRIDGE, Mass., Feb. 6, 2017 /PRNewswire/ -- Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) will be participating in the 2017 BIO CEO & Investor Conference in New York City on Monday, February 13, 2017. During the conference, Joseph Pearlberg, M.D., Ph.D., vice president, clinical development at Infinity will participate in a panel at 11:00 a.m. ET entitled, "CAR-T, TILs, and Bispecifics: Immuno-Oncology Challenges and Opportunities." Additionally, Adelene Perkins, Infinity's chair and ... 
Infinity Presents Preclinical Data and Phase 1 Clinical Data on IPI-549 at PI3K Keystone Symposia Conference
Jan 20, 2017
- Inhibition of PI3K-Gamma by IPI-549 Can Overcome Tumor Resistance to Checkpoint Inhibitors in Preclinical Models - CAMBRIDGE, Mass., Jan. 20, 2017 /PRNewswire/ -- Today, during a plenary session at the Keystone Symposia Conference, "PI3K Pathways in Immunology, Growth Disorders and Cancer," Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) presented preclinical data for IPI-549, an oral immuno-oncology development candidate that selectively inhibits phosphoinositide-3-kinase-gamma (PI3K-gamma... 
Infinity Provides 2017 Goals and Financial Guidance
Jan 09, 2017
- Updated Data From Phase 1 Study of IPI-549, an Immuno-Oncology Development Candidate Targeting PI3K-Gamma, Anticipated in 2017 - - Presentation on IPI-549 to Be Featured in a Plenary Session at the Upcoming PI3K Keystone Symposia Conference - - 2017 Financial Guidance Projects Cash Runway Into the First Quarter of 2019 - - Company to Present at 35thAnnual J.P. Morgan Healthcare Conference on January 12 at 10:30 a.m. PT (1:30 p.m. ET) - CAMBRIDGE, Mass., Jan. 9, 2017 /PRNewswire/ ... 
Infinity To Present At 35th Annual J.P. Morgan Annual Healthcare Conference
Jan 05, 2017
CAMBRIDGE, Mass., Jan. 5, 2017 /PRNewswire/ -- Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) will be presenting at the 35th Annual J.P. Morgan Healthcare Conference on Thursday, January 12, 2017, at 10:30 a.m. PT (1:30 p.m. ET) in San Francisco, CA. A live webcast of Infinity's presentation will be accessible on the Investors/Media section of Infinity's website at www.infi.com, and will be available for 30 days following the event. About Infinity Infinity is... 
Infinity Announces Organizational Changes
Jan 04, 2017
-- Lawrence Bloch Promoted to President -- -- Julian Adams to Retire -- -- Additional Senior Promotions Announced -- CAMBRIDGE, Mass., Jan. 4, 2017 /PRNewswire/ -- Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced that Lawrence Bloch, M.D., J.D., has been promoted to president. In his new role, Dr. Bloch will retain responsibility for the finance, business development, corporate communications and investor relations functions at Infinity and will assume responsibility for ...